Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.48 |
| ▸ | DAO | P14920 | 2/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | DHODH | Q02127 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 8/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | RXRB | P28702 | 1/20 | 0.39 |
| ▸ | RXRG | P48443 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1295021 | 0.87 | RXRA (0.41) | IDO1DAODHODHTACR1TAAR1 | |
| SCHEMBL80590 | 0.86 | IDO1 (0.45) | IDO1DAOCES2DHODHTACR1 | |
| SCHEMBL3985022 | 0.86 | NOTUM (0.41) | IDO1DAODHODHTACR1TAAR1 | |
| SCHEMBL12398665 | 0.86 | IDO1 (0.41) | IDO1DAODHODHTACR1TAAR1 | |
| SCHEMBL10316301 | 0.86 | NOS1 (0.42) | IDO1DAODHODHTACR1TAAR1 | |
| SCHEMBL24214278 | 0.81 | MRGPRX4 (0.50) | CES2DHODHTACR1RXRARXRB | |
| SCHEMBL31736118 | 0.81 | DAO (0.36) | IDO1DAOCES2DHODHTACR1 | |
| SCHEMBL15738902 | 0.80 | IDO1 (0.44) | IDO1DAOCES2DHODHTACR1 | |
| SCHEMBL265486 | 0.80 | IDO1 (0.52) | IDO1DAOCES2TACR1RXRA | |
| SCHEMBL156739 | 0.79 | TAAR1 (0.67) | IDO1DAODHODHTAAR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106399398-B | Biological preparation method of (R) -3, 5-bis (trifluoromethyl) phenethyl alcohol | 上海医药工业研究院 | 2024-07-09 | — | — | CN | claimed |
| CN-117778341-A | Immobilized carbonyl reductase based on protein tag self-assembly and application of immobilized carbonyl reductase in continuous catalysis preparation of aprepitant intermediate | 浙江工业大学 | 2024-03-29 | — | — | CN | claimed |
| CN-113388627-A | Reductase LX05 gene, genetic engineering bacterium containing gene and application of gene | 湖南科技大学 | 2021-09-14 | — | — | CN | claimed |
| CN-112048538-A | Method for preparing (S) - [3, 5-bis (trifluoromethyl) phenyl ] ethanol by using Verticillium terrestris | 浙江工业大学 | 2020-12-08 | — | — | CN | claimed |
| CN-107326049-A | Recombinate ketoreductase and prepare (R) -3,5- two（Trifluoromethyl）Application in benzyl carbinol | 尚科生物医药（上海）有限公司 | 2017-11-07 | — | — | CN | claimed |
| EP-2970927-A1 | IMMOBILIZED KETOREDUCTASES AND PROCESS FOR MAKING AND USING IMMOBILIZED KETOREDUCTASE | Merck Sharp & Dohme Corp. (US) | 2016-01-20 | — | — | EP | claimed |
| CN-103773724-B | Rhodococcus XS1012 and preparing the application in chiral alcohol | JIANG University OF TECHNOLOGY (CN) | 2016-01-20 | — | — | CN | claimed |
| WO-2014150633-A1 | IMMOBILIZED KETOREDUCTASES AND PROCESS FOR MAKING AND USING IMMOBILIZED KETOREDUCTASE | MERCK SHARP & DOHME CORP. (US) | 2014-09-25 | — | — | WO | claimed |
| CN-103773724-A | Rhodococcus erythropolis XS1012 and application thereof in preparation of chiral alcohol | UNIV ZHEJIANG TECHNOLOGY | 2014-05-07 | — | — | CN | claimed |
| JP-2006521344-A | — | — | 2006-09-21 | — | — | JP | claimed |
| EP-1622872-A1 | 1,2,4-SUBSTITUERTE 1,2,3,4-TETRAHYDRO-AND 1,2 DIHYDRO-QUINOLINE AND 1,2,3,4-TETRAHYDRO-QUINOXALINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND OBESITY | Pfizer Products Inc. (US) | 2006-02-08 | — | — | EP | claimed |
| WO-2004094353-A1 | PROCESS FOR THE MANUFACTURE OF 3,5-BIS(TRIFLUOROMETHYL)PHENYL-1-HYDROXYETHANE AND DERIVATIVE THEREOF | MITENI S.P.A. (IT) | 2004-11-04 | — | — | WO | claimed |
| WO-2004094358-A1 | PROCESS FOR THE MANUFACTURE OF 3,5-BIS(TRIFLUOROMETHYL)ACETOPHENONE | MITENI S.P.A. (IT) | 2004-11-04 | — | — | WO | claimed |
| US-20040204450-A1 | Quinoline and quinoxaline compounds | PFIZER INC | 2004-10-14 | — | — | US | claimed |
| WO-2004085401-A1 | 1,2,4-SUBSTITUTED 1,2,3,4-TETRAHYDRO-AND 1,2 DIHYDRO-QUINOLINE AND 1,2,3,4-TETRAHYDRO-QUINOXALINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND OBESITY | PFIZER PRODUCTS INC. (US) | 2004-10-07 | — | — | WO | claimed |
| EP-1292583-A4 | PROCESS FOR THE SYNTHESIS OF (2R, 2-ALPHA-R)-4-BENZYL-2- 1-(3,5-BIS(TRIFLUOROMETHYL)PHENYL)ETHOXY]-1,4-OXAZIN-3-ONE | MERCK & CO INC (US) | 2004-02-25 | — | — | EP | claimed |
| EP-1292583-A1 | PROCESS FOR THE SYNTHESIS OF (2R, 2-ALPHA-R)-4-BENZYL-2- 1-(3,5-BIS(TRIFLUOROMETHYL)PHENYL)ETHOXY]-1,4-OXAZIN-3-ONE | Merck & Co., Inc. (US) | 2003-03-19 | — | — | EP | claimed |
| EP-1196364-A1 | PROCESS FOR THE SYNTHESIS OF (R)-1-(3,5-BIS(TRIFLUOROMETHYL)-PHENYL)ETHAN-1-OL BY ASYMMETRIC TRANSFER HYDROGENATION | Merck & Co., Inc. (US) | 2002-04-17 | — | — | EP | claimed |
| WO-2001094323-A1 | PROCESS FOR THE SYNTHESIS OF (2R, 2-ALPHA-R)-4-BENZYL-2-[1-(3,5-BIS(TRIFLUOROMETHYL)PHENYL)ETHOXY]-1,4-OXAZIN-3-ONE | MERCK & CO., INC. (US) | 2001-12-13 | — | — | WO | claimed |
| WO-2001002326-A1 | PROCESS FOR THE SYNTHESIS OF (R)-1-(3,5-BIS(TRIFLUOROMETHYL)-PHENYL)ETHAN-1-OL BY ASYMMETRIC TRANSFER HYDROGENATION | MERCK & CO., INC. (US) | 2001-01-11 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204450-A1 | Quinoline and quinoxaline compounds | LDLR, APOB, PON1 | IDO1 1293/4885DAO 2279/4885CES2 487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.